Floatz logo

Acthar

Relapsing-Remitting Multiple Sclerosis

Mallinckrodt ARD LLCUNKNOWNPhase 4 / ApprovedDormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

71 Active assets in the Relapsing-Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Fingolimod
TG Therapeutics, Inc.
Phase 4BBB
Interferon ?1 (Human Fibroblast Protein Moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB

View all 50 →

Same molecule, other indications

Acthar is also rated in:

autoimmune diseaseActive
CCC
Indicative · Phase 4
48 / 100
View asset →
dry eye syndromeActive
CCC
Indicative · Phase 4
48 / 100
View asset →
neurotrophic keratopathyActive
CCC
Indicative · Phase 4
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →